Dimensionality and Measurement Invariance of the Italian Version of the EORTC QLQ-C30 in Postoperative Lung Cancer Patients.
EORTC QLQ-C30
assessment
lung cancer
measurement invariance
quality of life
validity
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
05
2019
accepted:
05
09
2019
entrez:
26
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
This study aims to validate and evaluate the psychometric properties and measurement invariance of the Italian version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), which is a measure of quality of life (QoL) for lung cancer patients after surgery. A total of 167 lung cancer patients completed the Italian version of the EORTC QLQ-C30 questionnaire at 30 days after they received a lobectomy. The factor structure of this scale was assessed by performing confirmatory factor analysis (CFA). Measurement invariance was evaluated by considering differential item functioning (DIF) due to age, gender, and type of surgery (i.e., robot- or not robot-assisted). The CFA demonstrated the validity of the factor structure of the EORTC QLQ-C30 in assessing overall health and eight distinct subscales of adverse events and functioning. Moreover, the results highlighted a minimal DIF with only trivial consequences on measurement invariance. Specifically, the DIF did not affect the mean differences of latent scores of QoL between patients undergoing robot-assisted surgery or traditional surgery. These findings supported the validity and suitability of the EORTC QLQ-C30 for the assessment of QoL in lung cancer patients of diverse ages and genders undergoing lobectomy with or without robot-assisted surgery.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to validate and evaluate the psychometric properties and measurement invariance of the Italian version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), which is a measure of quality of life (QoL) for lung cancer patients after surgery.
METHODS
METHODS
A total of 167 lung cancer patients completed the Italian version of the EORTC QLQ-C30 questionnaire at 30 days after they received a lobectomy. The factor structure of this scale was assessed by performing confirmatory factor analysis (CFA). Measurement invariance was evaluated by considering differential item functioning (DIF) due to age, gender, and type of surgery (i.e., robot- or not robot-assisted).
RESULTS
RESULTS
The CFA demonstrated the validity of the factor structure of the EORTC QLQ-C30 in assessing overall health and eight distinct subscales of adverse events and functioning. Moreover, the results highlighted a minimal DIF with only trivial consequences on measurement invariance. Specifically, the DIF did not affect the mean differences of latent scores of QoL between patients undergoing robot-assisted surgery or traditional surgery.
CONCLUSION
CONCLUSIONS
These findings supported the validity and suitability of the EORTC QLQ-C30 for the assessment of QoL in lung cancer patients of diverse ages and genders undergoing lobectomy with or without robot-assisted surgery.
Identifiants
pubmed: 31649573
doi: 10.3389/fpsyg.2019.02147
pmc: PMC6792474
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2147Informations de copyright
Copyright © 2019 Marzorati, Monzani, Mazzocco, Pavan, Monturano and Pravettoni.
Références
Qual Life Res. 2007 Feb;16(1):115-29
pubmed: 17109190
Br J Cancer. 2004 Jun 14;90(12):2288-96
pubmed: 15162156
J Clin Oncol. 2005 Oct 1;23(28):6865-72
pubmed: 16192578
Support Care Cancer. 2011 Nov;19(11):1753-60
pubmed: 20886240
Psychooncology. 2018 Feb;27(2):703-705
pubmed: 28574170
Lung Cancer. 2018 Sep;123:149-154
pubmed: 30089587
Ann Oncol. 2017 Nov 1;28(11):2874-2881
pubmed: 28945875
Qual Life Res. 2015 Jan;24(1):125-33
pubmed: 25193618
Qual Life Res. 2009 Apr;18(3):371-80
pubmed: 19221893
Eur J Intern Med. 2014 Oct;25(8):685-8
pubmed: 25060407
Patient Prefer Adherence. 2017 Sep 06;11:1497-1503
pubmed: 28919722
Br J Surg. 2014 Mar;101(4):371-82
pubmed: 24474151
PLoS One. 2014 Feb 12;9(2):e88321
pubmed: 24533075
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Psychol Assess. 2014 Mar;26(1):307-13
pubmed: 24059477
Onco Targets Ther. 2016 Feb 29;9:1023-8
pubmed: 27013895
Eur J Cancer. 2000 Sep;36(14):1796-807
pubmed: 10974628
J Eval Clin Pract. 2011 Aug;17(4):594-6
pubmed: 21679280
Innovations (Phila). 2007 Nov;2(6):261-92
pubmed: 22437196
Health Econ Rev. 2013 May 16;3(1):15
pubmed: 23680096
Ann Thorac Surg. 2014 Jul;98(1):203-8; discussion 208-9
pubmed: 24793685
Qual Life Res. 2019 Jul;28(7):1849-1861
pubmed: 30825160
BMC Cancer. 2011 Aug 15;11:353
pubmed: 21843358
Ann Oncol. 2006 Nov;17(11):1698-704
pubmed: 16968876
Qual Life Res. 2006 Aug;15(6):1103-15; discussion 1117-20
pubmed: 16900290
Int J Gynecol Cancer. 2015 Oct;25(8):1534-40
pubmed: 26244759
Ann Oncol. 1998 May;9(5):549-57
pubmed: 9653497
Nicotine Tob Res. 2019 Jan 1;21(1):119-126
pubmed: 29660034
Patient Relat Outcome Meas. 2018 Nov 01;9:353-367
pubmed: 30464666
Health Qual Life Outcomes. 2018 Sep 14;16(1):183
pubmed: 30217200
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Tumori. 2002 Mar-Apr;88(2):110-6
pubmed: 12088249
J Res Adolesc. 2016 Dec;26(4):687-695
pubmed: 28453201